PF-Atlas › Clinical Trials › NCT07687459

Study Evaluation Rentosertib Administered Orally in Patients With Idiopathic Pulmonary Fibrosis

INS018_055 tablets · Phase 3

Registry ID
NCT07687459
Phase
Phase 3
Status
Not yet recruiting
Drug / intervention
INS018_055 tablets
Sponsor
InSilico Medicine Hong Kong Limited
Start
2026-08-30
Enrollment
320
Locations
47

About this trial

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018\_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis. The purpose of this study is to evaluate if Rentosertib (INS018\_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018\_055). In this study, Rentosertib (INS018\_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018\_055) works to treat Idiopathic Pulmonary Fibrosis.

View NCT07687459 on ClinicalTrials.gov →

Explore related

All INS018_055 tablets trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT07687459 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.